Search research articles
Contact Us
Filters
Showing results (1-10 of 37) with videos related to
Page
of 4
Sort By:
JCO Precision Oncology
|
January 7, 2022
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation
Melinda A Pruis, M S Paats, W R R Geurts, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 14, 2020
Letter to the Editor
J H R J Degens, A-M C Dingemans, A M W J Schols, et al.
British Journal of Cancer
|
October 20, 2012
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
J L Kuiper, J S W Lind, H J M Groen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 10, 2020
Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature
B C M Hermans, J L Derks, L Moonen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 23, 2008
Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study
D De Ruysscher, A Botterweck, M Dirx, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2013
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study
J G Aerts, H Codrington, N A G Lankheet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 2, 2015
Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study
L E Hendriks, J L Derks, P E Postmus, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 1, 2012
Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?
D De Ruysscher, J Van Meerbeeck, K Vandecasteele, et al.
Respiratory Medicine and Research
|
September 27, 2020
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy
C Lefebvre, E Martin, L E L Hendriks, et al.
Respiratory Medicine
|
December 4, 2014
Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study
E P A T Gommans, P Even, C F M Linssen, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 37) with videos related to
Sort By:
Page
of 4
JCO Precision Oncology
|
January 7, 2022
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation
Melinda A Pruis, M S Paats, W R R Geurts, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 14, 2020
Letter to the Editor
J H R J Degens, A-M C Dingemans, A M W J Schols, et al.
British Journal of Cancer
|
October 20, 2012
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
J L Kuiper, J S W Lind, H J M Groen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 10, 2020
Pulmonary neuroendocrine neoplasms with well differentiated morphology and high proliferative activity: illustrated by a case series and review of the literature
B C M Hermans, J L Derks, L Moonen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 23, 2008
Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study
D De Ruysscher, A Botterweck, M Dirx, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 30, 2013
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study
J G Aerts, H Codrington, N A G Lankheet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 2, 2015
Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study
L E Hendriks, J L Derks, P E Postmus, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
May 1, 2012
Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?
D De Ruysscher, J Van Meerbeeck, K Vandecasteele, et al.
Respiratory Medicine and Research
|
September 27, 2020
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy
C Lefebvre, E Martin, L E L Hendriks, et al.
Respiratory Medicine
|
December 4, 2014
Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study
E P A T Gommans, P Even, C F M Linssen, et al.
Page
of 4